MiMedx Group
MiMedx Group (NASDAQ: MDXG) is a publicly traded therapeutic biologics company that develops and commercializes placental tissue allograft products for wound care and surgical applications, serving healthcare providers across the United States through direct sales, GPO agreements, and exclusive distribution partnerships.
- Company typePublic
- Founded2008
- HeadquartersMarietta, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What MiMedx Group does
MiMedx Group, Inc. (NASDAQ: MDXG) is a publicly traded therapeutic biologics company headquartered in Marietta, Georgia, that develops, manufactures, and commercializes placental tissue allograft products for wound care and surgical applications. The company's core technology is the proprietary PURION processing method applied to donated human placental tissue, yielding Dehydrated Human Amnion Chorion Membrane (DHACM) and Lyophilized Human Amnion Chorion Membrane (LHACM) products including EPIFIX, EPICORD, EPIEFFECT, CHORIOFIX, AMNIOFIX, and AMNIOCORD. These products are sold across two segments: Advanced Wound Solutions for chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions for soft tissue repair across multiple surgical specialties. The portfolio is supported by over 85 U.S. patents, FDA registration, AATB accreditation, and state tissue bank licenses across seven states.
The company generates revenue through one-time product sales to healthcare providers, with reimbursement sourced from Medicare, Medicaid, and commercial payers. Go-to-market combines direct field sales (20+ Field Reimbursement Managers), GPO agreements with Premier and Vizient, and exclusive distribution partnerships (Regen Lab USA for RegenKit-Wound Gel, Gel4Med for G4Derm Plus). The MIMEDX CONNECT digital platform supports ordering and insurance verification. Key customer segments include wound care clinicians, surgeons across 10+ specialties, hospital systems and IDNs, and underserved uninsured patients through a Patient Assistance Program. The company's revenue base contracted sharply in Q1 2026 (down 33% YoY to $59M) following Medicare reimbursement reforms effective January 2026 that drove a 60% decline in the wound care segment, while the surgical segment grew 13% YoY. In response, management initiated a $40M cost reduction program including a 15% workforce reduction targeting Q3 2026 breakeven.
MiMedx Group firmographics
Firmographics- Name
- MiMedx Group
- Legal name
- MIMEDX Group, Inc.
- Website
- http://mimedx.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- MiMedx Group (NASDAQ: MDXG) is a publicly traded therapeutic biologics company that develops and commercializes placental tissue allograft products for wound care and surgical applications, serving healthcare providers across the United States through direct sales, GPO agreements, and exclusive distribution partnerships.
- Ownership category
- akta.pro rank
MiMedx Group industry classification
Industry- Product category
- Regenerative Medicine / Wound Care Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)
Keywords
Where MiMedx Group is headquartered
LocationHeadquarters
- HQ city
- Marietta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MiMedx Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others
Revenue model
- Advanced Wound Care Products: Sales of placental allograft products (EPIFIX, EPICORD, EPIEFFECT, EPIXPRESS, CELERA, EMERGE, CHORIOFIX) for chronic wound treatment including diabetic foot ulcers and venous leg ulcers. Q1 2026 wound sales dropped 60% YoY to $22.6M due to Medicare reimbursement headwinds.
- Advanced Surgical Products: Sales of surgical allograft products (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) for surgical applications including burn, trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular procedures. Grew 13% YoY in Q1 2026.
- RegenKit-Wound Gel Distribution: Exclusive U.S. distribution of RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel (HCPCS code G0465) covered nationally by CMS for diabetic chronic wounds.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Product catalog with multiple size configurations and billing units |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
MiMedx Group product offering
Product offeringCore offering
MiMedx Group manufactures and distributes PURION-processed placental tissue allograft products for wound care and surgical recovery. Its portfolio spans Advanced Wound Solutions (EPIFIX, EPICORD, EPIEFFECT, CELERA, EMERGE, EPIXPRESS, CHORIOFIX, RegenKit-Wound Gel) targeting chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) serving surgical applications across burn/trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular specialties. Products are sold to healthcare providers in the United States with reimbursement through Medicare, Medicaid, and commercial payers.
Product overview
MiMedx Group is a therapeutic biologics company and pioneer in placental biologics offering a broad portfolio of advanced wound care and surgical products. The product portfolio consists of two main categories: Advanced Wound Solutions (EPIFIX, EPICORD, EPIXPRESS, CELERA, EMERGE, CHORIOFIX, RegenKit-Wound Gel) designed for wound care clinicians treating chronic and hard-to-heal wounds; and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) for surgical applications across multiple specialties including burn and trauma, foot and ankle, colorectal, gynecologic, orthopedic, plastic, spine, thyroid, and vascular surgery. All placental products are processed using proprietary PURION methodology and are backed by extensive clinical evidence including the largest body of Level I evidence among placental allograft products.
Differentiator
Problem solved
Functional benefit
Brands
- EPIFIX: Dehydrated Human Amnion/Chorion Membrane product for wound care applications
- EPICORD
- EPIEFFECT
- EPIXPRESS
- CELERA
- EMERGE
- CHORIOFIX
- AMNIOFIX
- AMNIOCORD
- AMNIOBURN
- AMNIOEFFECT
- AXIOFILL
- HELIOGEN
- G4Derm Plus
- Hydrelix
- RegenKit-Wound Gel
Products and services
- EPIFIX Dehydrated Human Amnion/Chorion Membrane (DHACM) allograft for advanced wound care, specifically indicated for diabetic foot ulcers and venous leg ulcers. Supported by extensive Level I clinical evidence including multiple RCTs.
- EPICORD Dehydrated Human Umbilical Cord allograft for wound care applications, providing a protective barrier for acute and chronic wounds. In a multicenter RCT, EPICORD demonstrated 81% complete wound closure at 12 weeks versus standard of care.
- EPIEFFECT Lyophilized Human Placental-Based Allograft Membrane designed as a protective barrier for wound treatment. Currently undergoing CAMPAIGN clinical trial evaluating performance against standard of care.
- CELERA Dehydrated Human Amniotic Membrane Allograft for wound care applications, offering another placental tissue-based option for clinicians.
- EMERGE Dual Membrane Placental Derived Matrix providing a protective barrier for acute and chronic wounds.
- EPIXPRESS Lyophilized Human Amniotic Membrane Allograft in fenestrated sheet form for wound care applications.
- CHORIOFIX Lyophilized Human Placental Allograft with unique triple-layer construction, the thickest in the MiMedx portfolio. Designed as a protective barrier for acute and chronic wounds including complex tunneling wounds, featuring uniform dual-sided design.
- RegenKit-Wound Gel FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. Distributed exclusively by MiMEDX in the U.S. under HCPCS code G0465 with national CMS coverage.
- AMNIOFIX Placental tissue allograft product for surgical applications in multiple surgical specialties.
- AMNIOCORD Placental tissue allograft for surgical applications.
- AMNIOBURN Placental tissue allograft specifically indicated for burn and trauma surgical applications.
- AMNIOEFFECT Placental tissue allograft for surgical applications.
- AXIOFILL Placental tissue allograft for surgical applications.
- HELIOGEN Placental tissue allograft for surgical applications.
- G4Derm Plus Flowable wound matrix product using self-assembling peptide technology. MiMEDX holds exclusive distribution rights in the United States. Launched nationwide with GPO agreements with Premier and Vizient.
- Hydrelix Placental tissue allograft for surgical applications.
Quantifiable outcome
- 92% complete wound closure at 6 weeks for diabetic foot ulcers treated with EPIFIX
- +4 more outcomes
Companies that use MiMedx Group
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
MiMedx Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
MiMedx Group partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Gel4Med, Inc.coreDistribution collaboration with Summit Products Group and MiMEDX for G4Derm Plus Biomimetic Matrix (BMM) product. Summit Products Group distributes G4Derm Plus alongside MiMEDX's portfolio, leveraging MiMEDX's established GPO and IDN contracting capabilities to accelerate hospital-system adoption in acute-care and surgical-suite markets.
- Regen Lab USA LLCcoreExclusive U.S. distribution agreement for RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. Product nationally covered by CMS under HCPCS code G0465, complementing MiMedx's Advanced Wound Care portfolio and strengthening competitive position ahead of January 1, 2026 CMS reimbursement changes.
- Regenity BiosciencescoreExclusive manufacturing and supply agreement granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications, expanding MiMedx's product portfolio into new technology areas.
- WoundGenexcorePremier Graft Purchasing Program partnership enabling healthcare providers to access advanced skin substitutes with no financial risk, deferred payment model, and clinical documentation support. Includes EPIFIX, EPIEFFECT, EPICORD, EPIXPRESS, and REGENKIT products for private practices (Places of Service 11, 12, 13, & 32).
- Premier and VizientcoreGroup purchasing organization agreements securing access to hospital networks for G4Derm Plus national launch. Agreements enable distribution across participating Premier and Vizient member hospital systems, providing group purchasing contracting for MiMedx's advanced wound care portfolio.
- CAMPAIGN Clinical Trial NetworkcoreClinical trial collaboration for EPIEFFECT product evaluation against standard of care in treating non-healing diabetic foot ulcers. Interim results from 71-88 enrolled patients demonstrating superior performance over SOC, supporting insurance coverage and future regulatory approvals.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
MiMedx Group competitors and assessment
Company assessmentBroad incumbents
- Integra LifeSciences: Diversified MedTech incumbent with a major wound care franchise (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel) and a surgical/regenerative tissue portfolio overlapping MiMedx's surgical solutions across multiple specialties.
- Smith+Nephew: Global wound care leader with advanced dressings (Allevyn, Acticoat), negative pressure wound therapy (PICO), and skin substitute products that compete directly with MiMedx's EPIFIX family in the chronic wound segment.
- ConvaTec: Advanced wound care portfolio (Aquacel, DuoDERM) with growing presence in skin substitutes and tissue regeneration, overlapping with MiMedx's hospital-based wound care channels through GPO contracts.
- 3M Health Care (KCI): Owner of KCI's V.A.C. negative pressure wound therapy franchise and former employer of several MiMedx executives (Kim Moller, John Harper, Eric Smith). Competes across wound care and surgical recovery with a far broader portfolio.
- Coloplast: Major wound and skin care franchise (Biatain, Comfeel) competing in advanced wound dressings; recently expanded into surgical biologics with the Kerecis fish-skin graft acquisition, a direct amniotic membrane substitute.
Direct peers
- Regen Lab SA: Swiss-based regenerative medicine company whose RegenKit-Wound Gel MiMedx now distributes exclusively in the U.S. Direct peer in PRP-based wound healing products; demonstrates the technology platform that MiMedx is leveraging to diversify away from placental allografts.
- LifeNet Health: Non-profit tissue processor and MiMedx's direct competitor in placental and dermal allografts (Dermacell, Arthroflex), with overlapping wound care and surgical reconstruction use cases and similar AATB-accredited processing capabilities.
- Amniox Medical (TissueTech): Direct competitor in cryopreserved and dehydrated amniotic membrane allografts (CLARIX, NEOX) for wound care and surgical applications, addressing the same podiatry, orthopedic, and surgical segments as MiMedx.
- Organogenesis Holdings: Direct competitor in skin substitutes and advanced wound care, marketing Apligraf (the head-to-head comparator for EPIFIX) and Dermagraft, plus the PuraPly wound matrix portfolio. Closest publicly traded comparable for placental and cellular allograft wound care economics.
Emerging players
- SurModics: Emerging player in drug-coated balloons and surface coating technologies for vascular and wound applications; competes in adjacent surgical intervention segments where MiMedx's AMNIOFIX and AMNIOBURN are positioned.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
MiMedx Group social profiles
Digital presenceMiMedx Group compliance and trust
Trust signalCompliance4 records
MiMedx Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiMedx Group leadership team
Management profileNumber of profiles
Profiles8 records
MiMedx Group funding detail
Funding detailFunding overview
Funding rounds8 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiMedx Group M&A and investment
M&A and investmentM&A3 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiMedx Group
What does MiMedx Group do?
MiMedx Group manufactures and distributes PURION-processed placental tissue allograft products for wound care and surgical recovery. Its portfolio spans Advanced Wound Solutions (EPIFIX, EPICORD, EPIEFFECT, CELERA, EMERGE, EPIXPRESS, CHORIOFIX, RegenKit-Wound Gel) targeting chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) serving surgical applications across burn/trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular specialties. Products are sold to healthcare providers in the United States with reimbursement through Medicare, Medicaid, and commercial payers.
Is MiMedx Group a public or private company?
MiMedx Group is a public company. It is classified as public and is currently operating.
When was MiMedx Group founded?
MiMedx Group was founded in 2008. It employs 501 to 1,000 people.
Where is MiMedx Group based?
MiMedx Group is headquartered in Marietta, United States, in the North America region.
How does MiMedx Group make money?
Three revenue lines are on record. Advanced Wound Care Products are the primary driver. The others are advanced Surgical Products and regenKit-Wound Gel Distribution.
Who are MiMedx Group's main competitors?
Broad incumbents on record are Integra LifeSciences, Smith+Nephew, ConvaTec, 3M Health Care (KCI) and Coloplast. Direct peers are Regen Lab SA, LifeNet Health, Amniox Medical (TissueTech) and Organogenesis Holdings. SurModics is listed as an emerging player.
Does MiMedx Group have an API?
No public API is recorded for MiMedx Group.
What industry is MiMedx Group in?
MiMedx Group's product category is Regenerative Medicine / Wound Care Biologics. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 3842.